Meyka Pro banner
Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. (CATX) Stock Overview

Explore Perspective Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

CATXAMEX
HealthcareMedical - Devices
$2.92
$0.07(2.34%)
U.S. Market opens in 2h 18m

Perspective Therapeutics, Inc. (CATX)

Meyka AI Score

Z

Key Financials

Market Cap226M
P/E Ratio-0.11
EPS (TTM)$-1.41
ROE-0.42%
Fundamental Analysis

AI Price Forecasts

1 Month$2.28
3 Months$5.07
1 Year Target$0.00

CATX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Perspective Therapeutics, Inc. (CATX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of C+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 39.48, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.00.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.11 and a market capitalization of 226M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-2.17%
5-Day Change
-5.03%
1-Month Change
-4.10%
3-Month Change
-35.71%
6-Month Change
20.37%
Year-to-Date (YTD) Change
6.36%
1-Year Change
-32.13%
3-Year Change
-52.36%
5-Year Change
-59.21%
All-Time (Max) Change
-94.26%

Contact Information

509 375 1202
2401 Elliott Avenue, Seattle, WA, 99354

Company Facts

1,660 Employees
IPO DateNov 10, 2005
CountryUS
Actively Trading

Frequently Asked Questions